Select Transactions

Avenue Therapeutics
Sale of Stock and Conditional Sale to
$215 million + CVRs
February 2019
Debt Recapitalization and Acquisition of NextWave Pharmaceuticals from
$125 million
September 2018
Rubicon Research
Majority recap by
General Atlantic Partners
$125 million
April 2019
Acquisition of
generics business of
$1.05 billion
June 2017
Torreya is a leading strategic M&A advisor to global life sciences companies.   MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales.   MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations.   MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals.   MORE

Creating Value Through China Partnering

Record Activity Level in Pharma In-Licensing in China

Torreya’s report provides an overview of burgeoning market for in-licensing of pharmaceutical products into China. Key points include:

Click Here for Report Executive Summary   |    Click Here for Full Report